NASDAQ:AVXL

Anavex Life Sciences - AVXL Stock Forecast, Price & News

$8.72

+0.04 (+0.46%)

(As of 03/24/2023 12:00 AM ET)

Add

Compare

Today's Range: $8.42
▼
$8.79
50-Day Range: $8.52
▼
$11.75
52-Week Range: $7.13
▼
$15.24

Volume: 1.08 million shs
Average Volume: 1.14 million shs
Market Capitalization: $680.42 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $41.80

Institutional Ownership

Anavex Life Sciences MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 379.4% Upside
$41.80 Price Target
Short Interest: Bearish
20.92% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.83
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.80) to ($0.65) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Medical Sector

372nd out of 1,005 stocks

Biological Products, Except Diagnostic Industry

65th out of 168 stocks

3.4

Analyst's Opinion

Consensus Rating
Anavex Life Sciences has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $41.80, Anavex Life Sciences has a forecasted upside of 379.4% from its current price of $8.72.
Amount of Analyst Coverage
Anavex Life Sciences has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
20.92% of the outstanding shares of Anavex Life Sciences have been sold short.
Short Interest Ratio / Days to Cover
Anavex Life Sciences has a short interest ratio ("days to cover") of 7.5.
Change versus previous month
Short interest in Anavex Life Sciences has recently decreased by 4.73%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Anavex Life Sciences does not currently pay a dividend.
Dividend Growth
Anavex Life Sciences does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Anavex Life Sciences has received a 73.63% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for genetic diseases", "Preclinical research services for mental health", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Anavex Life Sciences is -0.83.

3.3

News and Social Media Coverage

News Sentiment
Anavex Life Sciences has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Anavex Life Sciences this week, compared to 1 article on an average week.
Search Interest
44 people have searched for AVXL on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.
MarketBeat Follows
Only 6 people have added Anavex Life Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Anavex Life Sciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
11.00% of the stock of Anavex Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 31.22% of the stock of Anavex Life Sciences is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Anavex Life Sciences are expected to grow in the coming year, from ($0.80) to ($0.65) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Anavex Life Sciences is -13.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Anavex Life Sciences is -13.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Anavex Life Sciences has a P/B Ratio of 4.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Anavex Life Sciences (NASDAQ:AVXL) Stock

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Receive AVXL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anavex Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

AVXL Stock News Headlines

March 17, 2023 | americanbankingnews.com

Anavex Life Sciences (NASDAQ:AVXL) Coverage Initiated by Analysts at StockNews.com

March 16, 2023 | markets.businessinsider.com

BTIG Remains a Buy on Anavex Life Sciences (AVXL)

March 25, 2023 | Investor Place Media (Ad)

Biden To Unleash "Choke Point" Operation On America?

Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.

March 15, 2023 | finance.yahoo.com

Wall Street Thinks This Small-Cap Stock Can Quadruple in Value

March 13, 2023 | finance.yahoo.com

Acadia (ACAD) Gets FDA Approval for Daybue for Rett Syndrome

March 9, 2023 | finance.yahoo.com

Anavex Life Sciences Appoints Former FDA Lead Neurology Statistician as Vice President Head of Biostatistics

March 6, 2023 | finance.yahoo.com

Why Shares of Anavex Life Sciences Rose 12.4% in February

February 23, 2023 | finance.yahoo.com

Is Anavex Life Sciences Stock a Buy Now?

March 25, 2023 | Investor Place Media (Ad)

Biden To Unleash "Choke Point" Operation On America?

February 7, 2023 | finanznachrichten.de

Anavex Life Sciences Corp.: Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results

February 7, 2023 | finance.yahoo.com

Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results

February 2, 2023 | msn.com

Anavex gains as trial for Rett syndrome candidate exceeds enrollment target

February 2, 2023 | finance.yahoo.com

Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial

January 30, 2023 | thestreet.com

Anavex Life Sciences (AVXL) Stock Soars on FDA Guidance

January 30, 2023 | seekingalpha.com

Approval For Anavex's Blarcamesine Looks Inevitable After Biogen's Leqembi Approved

January 20, 2023 | finance.yahoo.com

FDA Rejects Accelerated Nod to Lilly's (LLY) Alzheimer's Drug

January 10, 2023 | msn.com

$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,000 Today

December 29, 2022 | seekingalpha.com

Biogen's Alzheimer's Drug Likely To Be Approved With Warning Labels

December 27, 2022 | msn.com

Here's How Much $100 Invested In Anavex Life Sciences 5 Years Ago Would Be Worth Today

December 21, 2022 | msn.com

Analyzing Anavex Life Sciences's Short Interest

December 17, 2022 | finance.yahoo.com

Anavex Life Sciences Stock Could 5x Before 2025 -- Here's Why

December 14, 2022 | finance.yahoo.com

Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial

December 8, 2022 | msn.com

Here's How Much You Would Have Made Owning Anavex Life Sciences Stock In The Last 5 Years

December 6, 2022 | seekingalpha.com

Anavex Life Sciences: The Little Company That Did

December 5, 2022 | finance.yahoo.com

Anavex's (AVXL) Lead Alzheimer's Drug Meets Study Goal

December 3, 2022 | markets.businessinsider.com

Berenberg Bank Reaffirms Their Buy Rating on Anavex Life Sciences (AVXL)

December 3, 2022 | finance.yahoo.com

Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive AVXL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anavex Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

AVXL Company Calendar

Last Earnings: 2/07/2023
Today: 3/25/2023
Next Earnings (Estimated): 5/09/2023
Fiscal Year End: 9/30/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AVXL
CUSIP: N/A
CIK: 1314052
Web: www.anavex.com
Phone: (844) 689-3939
Fax: N/A
Employees: 25
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $41.80
High Stock Price Forecast: $80.00
Low Stock Price Forecast: $11.00
Forecasted Upside/Downside: +379.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.65)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-47,980,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -34.50%
Return on Assets: -32.22%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 11.20
Quick Ratio: 11.20

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.83 per share
Price / Book: 4.77

Miscellaneous

Outstanding Shares: 78,030,000
Free Float: 69,448,000
Market Cap: $680.42 million
Optionable: Optionable
Beta: 0.75

Key Executives

Christopher U. Missling
Chairman, President, CEO & Secretary

Stephan Toutain
Chief Operating Officer

Sandra Boenisch
Chief Financial Officer & Treasurer

Walter E. Kaufmann
Chief Scientific Officer

Edward R. Hammond
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AVXL Stock - Frequently Asked Questions

Should I buy or sell Anavex Life Sciences stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Anavex Life Sciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVXL shares.
View AVXL analyst ratings or view top-rated stocks.
What is Anavex Life Sciences' stock price forecast for 2023?: 4 Wall Street analysts have issued 1-year price targets for Anavex Life Sciences' shares. Their AVXL share price forecasts range from $11.00 to $80.00. On average, they expect the company's share price to reach $41.80 in the next year. This suggests a possible upside of 379.4% from the stock's current price.
View analysts price targets for AVXL or view top-rated stocks among Wall Street analysts.
How have AVXL shares performed in 2023?: Anavex Life Sciences' stock was trading at $9.26 at the beginning of 2023. Since then, AVXL shares have decreased by 5.8% and is now trading at $8.72.
View the best growth stocks for 2023 here.
When is Anavex Life Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our AVXL earnings forecast.
How were Anavex Life Sciences' earnings last quarter?: Anavex Life Sciences Corp. (NASDAQ:AVXL) posted its quarterly earnings results on Tuesday, February, 7th. The biotechnology company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.20) by $0.03.
What ETFs hold Anavex Life Sciences' stock?: ETFs with the largest weight of Anavex Life Sciences (NASDAQ:AVXL) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Biotech ETF (XBI), ALPS Medical Breakthroughs ETF (SBIO), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares Biotechnology ETF (IBB).

What other stocks do shareholders of Anavex Life Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Anavex Life Sciences investors own include Inovio Pharmaceuticals (INO), POET Technologies (POETF), Brainstorm Cell Therapeutics (BCLI), LadRx (CYTR), Sanchez Energy (SN), Novavax (NVAX), Geron (GERN), VASCO Data Security International (VDSI), Sorrento Therapeutics (SRNE) and OPKO Health (OPK).
What is Anavex Life Sciences' stock symbol?: Anavex Life Sciences trades on the NASDAQ under the ticker symbol "AVXL."
Who are Anavex Life Sciences' major shareholders?: Anavex Life Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (1.80%), Silverarc Capital Management LLC (0.00%), Millennium Management LLC (1.07%), Susquehanna International Group LLP (0.00%), Charles Schwab Investment Management Inc. (0.72%) and Morgan Stanley (0.49%). Insiders that own company stock include Athanasios Skarpelos, Elliot Favus, Elliot Favus, Peter DO Donhauser and Sandra Boenisch.
View institutional ownership trends.
How do I buy shares of Anavex Life Sciences?: Shares of AVXL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Anavex Life Sciences' stock price today?: One share of AVXL stock can currently be purchased for approximately $8.72.
How much money does Anavex Life Sciences make?: Anavex Life Sciences (NASDAQ:AVXL) has a market capitalization of $680.42 million. The biotechnology company earns $-47,980,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis.
How can I contact Anavex Life Sciences?: Anavex Life Sciences' mailing address is 51 W 52ND STREET 7TH FLOOR, NEW YORK NY, 10019. The official website for the company is www.anavex.com. The biotechnology company can be reached via phone at (844) 689-3939 or via email at ir@anavex.com.

This page (NASDAQ:AVXL) was last updated on 3/25/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Anavex Life Sciences - AVXL Stock Forecast, Price & News

Anavex Life Sciences MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Anavex Life Sciences (NASDAQ:AVXL) Stock

AVXL Stock News Headlines

AVXL Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

AVXL Stock - Frequently Asked Questions

Overall MarketRank^™